Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model

Human Gene Therapy

Volumn 22, Issue 9, 2011, Pages 1095-1100

  Weaver, Eric A ^a   Chen, Christopher Y ^a   May, Shannon M ^a   Barry, Mary E ^a   Barry, Michael A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN; ONCOLYTIC ADENOVIRUS; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BAGG ALBINO MOUSE; CANCER IMMUNIZATION; CANCER MODEL; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN ADENOVIRUS; IMMUNOCOMPETENCE; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SEROTYPE; TUMOR GROWTH; VIRUS CARCINOGENESIS;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNIZATION; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; ONCOLYTIC VIRUSES;

CRICETINAE; HUMAN ADENOVIRUS; MUS;

EID: 80053049548     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.071     Document Type: Article

References (27)

1. Armstrong, A.C., Dermime, S., Allinson, C.G., et al. (2002). Immunization with a recombinant adenovirus encoding a lym-phoma idiotype: Induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J. Immunol. 168, 3983-3991. (Pubitemid 34298403)
2. Barry, M.A., Behnke, C.A., and Eastman, A. (1990). Activation of programmed cell death (apoptosis) by cisplatin, other anti-cancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353-2362. (Pubitemid 20373997)
3. Chen, C.Y., Weaver, E.A., Khare, R., et al. (2011a). Mining the adenovirus virome for effective oncolytics against breast and ovarian cancer. Cancer Gene Ther. 1-7.
4. Chen, C.Y., Weaver, E.A., Khare, R., et al. (2011b). Species D adenoviruses as oncolytics against B cell cancers. Clin. Cancer Res. (In Press).
5. Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., et al. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin, Oncol, 17, 268-276. (Pubitemid 29022402)
6. Demierre, M.F., Higgins, P.D., Gruber, S.B., et al. (2005). Statins and cancer prevention. Nat. Rev. 5, 930-942. (Pubitemid 41766782)
7. Doenecke, A., Winnacker, E.L., and Hallek, M. (1997). Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from mu-rine and human lymphoma cells and cell lines. Leukemia 11, 1787-1792. (Pubitemid 27458620)
8. Faber, M., Li, J., Kean, R.B., et al. (2009). Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl. Acad. Sci. U.S.A. 106, 11300-11305.
9. Fueyo, J., Gomez-Manzano, C., Alemany, R., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12. (Pubitemid 30066345)
10. Gromeier, M., Lachmann, S., Rosenfeld, M.R., et al. (2000). In-tergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 97, 6803-6808. (Pubitemid 30412795)
11. Hakim, I., Levy, S., and Levy, R.(1996). A nine-amino acid peptide from IL-1b augments antitumor immune responses induced by protein and DNA vaccines. J. Immunol. 157, 5503-5511. (Pubitemid 126448971)
12. Hirasawa, K., Nishikawa, S.G., Norman, K.L., et al. (2002). On-colytic reovirus against ovarian and colon cancer. Cancer Res. 62, 1696-1701. (Pubitemid 34408491)
13. Kim, K.J., Kanellopoulos-Langevin, C., Merwin, R.M., et al. (1979). Establishment and characterization of BALB/c lym-phoma lines with B cell properties. J. Immunol. 122, 549-554. (Pubitemid 9089211)
14. King, C.A., Spellerberg, M.B., Zhu, D., et al. (1998). DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4, 1281-1286. (Pubitemid 28512109)
15. Kirn, D.H., Wang, Y., Le Boeuf, F., et al. (2007). Targeting of interferon-b to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353.
16. Nakamura, T., Peng, K.W., Harvey, M., et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23, 209-214. (Pubitemid 40255331)
17. Nettelbeck, D.M., Rivera, A.A., Balague, C., et al. (2002). Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 62, 4663-4670.
18. Parato, K.A., Senger, D., Forsyth, P.A., and Bell, J.C. (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. 5, 965-976. (Pubitemid 41766784)
19. Reid, T., Galanis, E., Abbruzzese, J., et al. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070-6079. (Pubitemid 35244455)
20. Rupprecht, C.E., and Gibbons, R.V. (2004). Clinical practice: Prophylaxis against rabies. N. Engl. J. Med. 351, 2626-2635. (Pubitemid 39628584)
21. Senac, J.S., Doronin, K., Russell, S.J., et al. (2010). Infection and killing of multiple myeloma by adenoviruses. Hum. Gene Ther. 21, 179-190.
22. Shashkova, E.V., May, S.M., and Barry, M.A. (2009). Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 394, 311-320.
23. Stevenson, F.K., Zhu, D., King, C.A., et al. (1995). Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 145, 211-228.
24. Stojdl, D.F., Lichty, B., Knowles, S., et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825. (Pubitemid 30469434)
25. Syrengelas, A.D., and Levy, R. (1999). DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection. J. Immunol. 162, 4790-4795. (Pubitemid 29314881)
26. Syrengelas, A.D., Chen, T.T., and Levy, R. (1996). DNA immunization induces protective immunity against B-cell lym-phoma. Nat. Med. 2, 1038-1041. (Pubitemid 26306846)
27. Todo, T., Martuza, R.L., Rabkin, S.D., and Johnson, P.A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98, 6396-6401. (Pubitemid 32488248)